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Crohn’s disease and ulcerative colitis, collectively known 
as the inﬂ  ammatory bowel diseases (IBD), are largely 
diseases of the twentieth century, and are associated 
with the rise of modern, Westernized industrial society. 
Although the causes of these diseases remain incom-
pletely understood, the prevailing model is that the in-
testinal ﬂ  ora drives an unmitigated intestinal immune 
response and inﬂ  ammation in the genetically suscepti-
ble host. A review of the past and present of these dis-
eases shows that detailed description preceded more 
fundamental elucidation of the disease processes. Work-
ing out the details of disease pathogenesis, in turn, has 
yielded dividends in more focused and effective therapy 
for IBD. This article highlights the key descriptions of 
the past, and the pivotal ﬁ  ndings of current studies in 
disease pathogenesis and its connection to medical ther-
apy. Future directions in the IBD will likely explicate 
the inhomogeneous causes of these diseases, with impli-
cations for individualized therapy.
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Past: the era of description
In the beginning, medical science was capable of de-
scribing the features of inﬂ  ammatory bowel disease 
(IBD), and medical therapeutics were guided by trial 
and error, misguided hypotheses about disease patho-
genesis, and some measure of serendipity. Crohn’s dis-
ease and ulcerative colitis—the two major forms of 
idiopathic IBD—have been recognized as distinct dis-
ease entities for over a century. As early as 1761 Mor-
gagni described intestinal inﬂ  ammation that in modern 
times we would recognize as Crohn’s disease.1 After the 
identiﬁ  cation of the causative agent of tuberculosis by 
Koch in 1882, it became clear that some individuals had 
a disease similar to intestinal tuberculosis but did not 
bear the tubercle bacillus. Reports by Fenwick in 1889, 
Dalziel in 1913, Weiner in 1914, Moschowitz and Wilen-
sky in 1923 and 1927, and Goldfarb and Suissman in 
1931 predated the landmark publication of Crohn, 
Ginzburg, and Oppenheimer in 1932 describing termi-
nal ileitis.1,2  Later, Lockhart-Mummery and Morson3 
described granulomatous colitis, and the disease pro-
cess was understood to potentially affect the large bowel 
as well. Thus, phenotypic distinction from ulcerative 
colitis was established. The historical origins of ulcer-
ative colitis are less clear, with descriptions of bloody 
diarrhea and dysentery dating back to antiquity. Gener-
ally, however, Wilkes is credited with the ﬁ  rst patho-
logic description of what was called simple ulcerative 
colitis in 1859.1  Subsequently, in 1875, Wilkes and 
Moxon described a syndrome of simple ulcerative coli-
tis in greater detail.1
With the recognition of the nosologic distinctions of 
these diseases came attempts to treat them surgically 
and medically (Table 1). Depending upon the etiologic 
concept of the disease, various therapies were attempt-
ed. For example, many conceived of the disease as being 
caused by an as yet unrecognized pathogen. Accord-
ingly, treatments have included potassium permanga-
nate, Dakin’s solution, antidysentery serum, Escherichia 
coli  vaccine, antiamoebic drugs, and sulfonamides.1 
These treatments did not prove to be durable or effec-
tive, and have all been abandoned over time. Sulfasala-
zine, the ﬁ  rst truly effective agent used in IBD, was 
discovered serendipitously when this antirheumatic 
agent was observed to produce resolution of both diar-
rhea and arthralgias in patients with ulcerative colitis 
being treated with this agent for their joint disease.
Further experimentation revealed that the active 
moiety of sulfasalazine was 5-aminosalicylate (5-ASA), 
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whereas the sulfa moiety was responsible for many of 
the untoward effects of the drug.4 Furthermore, delivery 
of the active 5-ASA molecule was ﬁ  nally understood to 
rely upon the presence of the diazo bond between the 
sulfapyridine and 5-ASA moieties for the delivery of 
the 5-ASA to the distal bowel upon cleavage of the 
bond by the colonic ﬂ  ora.5  Subsequently, a host of 
second-generation 5-ASA agents were developed that 
utilized a variety other mechanisms to deliver the drug 
topically to the distal bowel. These have included time-
released and pH-dependent agents, as well as non-sulfa-
containing diazo-bonded agents such as olsalazine and 
balsalazide.
The descriptive histology of IBD suggested that im-
mune activation could also be targeted by therapeutic 
agents. The observation of acute and chronic inﬂ  amma-
tory cells, and the common occurrence of extraintestinal 
immune-mediated manifestations eventually led to the 
use of adrenocorticotropic hormone6  and corticoste-
roids,7 which have proven to be highly effective in treat-
ing these diseases. The ﬁ  rst randomized controlled trial 
of hydrocortisone in ulcerative colitis proved the agent 
to be remarkably effective,8 and ﬁ  nally produced effec-
tive therapy for severe ulcerative colitis, which previ-
ously had been associated with a considerably high case 
fatality rate.
Nevertheless, the corticosteroids have proven to be a 
double-edged sword in the treatment of IBD. Evidence 
from population-based cohorts suggests that although 
less than half of patients with IBD require treatment 
with these agents, the need for corticosteroids is associ-
ated with a worse prognosis, including increased risk of 
surgery and risk of disability.9 In all, slightly more than 
half of individuals treated with glucocorticoids will be 
well and off steroids at 1 year after beginning these 
agents.
Consequently, more potent immunomodulatory 
agents were explored for the treatment of IBD. Mer-
captopurine and azathioprine were initially disappoint-
ing in clinical trials in Crohn’s disease until appropriate 
dosing and duration of therapy were more fully expli-
cated. With the landmark study of Present et al.,10 
mercaptopurine and azathioprine assumed their place 
in the IBD armamentarium as treatments primarily 
for patients who were steroid-refractory or steroid-
dependent. These agents are also thought to be effec-
tive in ﬁ  stulizing Crohn’s disease.11 More recently, these 
agents have been more fully accepted as appropriate 
therapies for the treatment of steroid-dependent to 
-refractory ulcerative colitis, as well.12  A second-line 
agent shown to be effective in steroid-dependent 
Crohn’s disease is methotrexate. This agent is effective 
both in the short term, to induce steroid-free remis-
sion,13 and in the long term, to maintain remission.14
Immunosuppressive therapy progressed further as 
increasingly potent agents became available. The intro-
duction of cyclosporine for treatment of severe, steroid-
refractory ulcerative colitis has provided an alternative 
to total proctocolectomy for some individuals.15 How-
ever, the narrow therapeutic margin of this agent has 
precluded widespread application, and in the United 
States its use remains conﬁ  ned largely to tertiary-care 
referral centers. Cyclosporine appears to be most effec-
tive when used as a bridge to maintenance therapy with 
mercaptopurine or azathioprine.16 The continued role 
of this agent becomes less certain with the advent of 
potent biologic agents effective in severe ulcerative 
colitis.
Surgical advances have also advanced the ﬁ  eld signiﬁ  -
cantly. The earliest surgeries for Crohn’s disease often 
sought to divert the fecal stream by bypassing surgery, 
rather than resection. Although effective, this technique 
has long been out of favor, with resection and primary 
anastomosis possible for the majority of patients with 
Crohn’s disease. More directly applicable to the opti-
mum care of patients was the appreciation that wide 
margins of resection were not effective in preventing 
disease recurrence.17 The important principle of bowel 
preservation in Crohn’s disease became favored in an 
effort to prevent short-bowel syndrome from repeated 
small-bowel resections. This principle of sparing the 
small bowel was carried further with the development 
of stricturoplasty techniques.18 Finally, the development 
in the 1980s of ileal pouch–anal anastomosis for patients 
Table 1.  Inﬂ  ammatory bowel disease landmarks of the past
•    Distinction of Crohn’s disease and ulcerative colitis from infectious colitis made possible by the development of 
bacteriologic techniques
•  Distinction between Crohn’s disease and ulcerative colitis drawn
• The  inﬂ  ammatory bowel diseases are understood to be immune-mediated diseases
•  Sulfasalazine and hydrocortisone used to treat ulcerative colitis
•  Thiopurine agents (mercaptopurine and azathioprine) used to treat IBD
•  Methotrexate used to treat Crohn’s disease and cyclosporine used to treat severe, steroid-refractory ulcerative colitis
•  Familial clustering implicates genetic factors in IBD
•  Bowel-sparing understood to be a key principle of surgical therapy, and the technique of stricturoplasty developed
•  Ileal pouch–anal anastomosis developed as an alternative to ileostomy after total proctocolectomy for ulcerative colitis
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with ulcerative colitis who required total proctocolec-
tomy was a revolutionary surgical advance that has 
provided a much needed alternative to permanent 
endileostomy.19
Present: the era of explanation
At present, key concepts regarding the pathogenesis of 
inﬂ  ammatory bowel disease are as follows (Table 2). 
First, it is recognized that immune tolerance is the nor-
mal state of the intestinal immune system. Second, it is 
apparent that a wide variety of cell types are orches-
trated in a tightly regulated fashion to maintain immu-
nologic tolerance. At the same time, the capacity to 
mount an immune and inﬂ  ammatory response within 
the mucosa is maintained. Third, the luminal ﬂ  ora is a 
key ingredient in the abnormal immune response of 
IBD. Fourth, genetic factors predispose individuals to 
an abnormal immune response to the ﬂ  ora. Finally, it is 
recognized that both the innate and adaptive immune 
responses play integrated roles in the homeostasis of the 
intestinal mucosal immune response.
For many years it has been recognized that the intes-
tinal mucosa contains a resident population of inﬂ  am-
matory cells. These cells are poised at the interface 
between the intestinal lumen and the systemic circula-
tion in readiness for enteric infection and other insults 
to the mucosa. When such an incursion occurs, the in-
evitable response is inﬂ  ammation. The key factor that 
differentiates individuals with IBD from normal indi-
viduals is the ability to downregulate that inﬂ  ammatory 
state and return it to a condition of normal, controlled 
gut inﬂ  ammation. By contrast, individuals susceptible 
to IBD will tend to enter a state of uncontrolled and 
chronic inﬂ  ammation with failure to downregulate the 
inﬂ  ammation caused by the insult.
Genetics have long been known to play a role in the 
susceptibility to IBD. Historically, it has been recog-
nized that approximately one in ﬁ  ve individuals newly 
diagnosed with IBD will report a family history. In ad-
dition, ﬁ  rst-degree relatives, in particular siblings, are at 
increased risk of IBD, and this risk is somewhat higher 
in individuals of Ashkenazi Jewish background.20 Third, 
there is a high concordance for Crohn’s disease among 
monozygotic twins, whereas a somewhat lesser concor-
dance is observed in monozygotic twins with one af-
fected individual with ulcerative colitis.21 These clues 
have long suggested that genetics play an important role 
in susceptibility to the inﬂ  ammatory bowel diseases.
Environmental contributions to the pathogenesis of 
IBD have also long been suspected. For many years, 
predominant theories have surrounded the notion that 
the mucosal inﬂ  ammation of IBD is an appropriate 
response to pathogenic microbiota.22  Candidates for 
pathogenic agents have been diverse over the years, and 
have included Diplostreptococcus, Entamoeba histoly-
tica, and, most persistently, Mycobacterium paratuber-
culosis.23 More recently, lines of evidence suggest that 
normal, nonpathogenic ﬂ  ora (at least in the conven-
tional sense of pathogenicity) are a necessary though 
not sufﬁ  cient factor in the pathogenesis of IBD, 
whereas ﬁ  rm evidence of a pathogenic agent has been 
lacking.
In addition to the host ﬂ  ora, other environmental 
factors have been noted to affect the expression of 
IBD. These factors may be considered to be disease 
modiﬁ  ers, and most prominently include smoking,24 
nonsteroidal anti-inﬂ  ammatory drugs,25  and prior ap-
pendectomy.26 In particular, both smoking and appen-
dectomy have been recognized to be distinct risk factors 
with dichotomous outcomes for Crohn’s disease and 
ulcerative colitis. Smoking has been associated with in-
creased risk of Crohn’s disease as well as worse out-
comes over the course of the disease,27  whereas for 
ulcerative colitis, smoking has been recognized as hav-
ing a protective effect.28–30 The effects of tobacco smoke 
are complex and poorly understood. The role of smok-
ing does not appear to be as simple as the presence or 
absence of nicotine, which may be an effective therapy 
for ulcerative colitis but is poorly tolerated.31 Current 
investigation focuses on the role of carbon monoxide in 
Table 2.  Landmarks of the present
• Controlled  physiologic  inﬂ  ammation is understood to result from the normal state of immune tolerance in the intestine
•    Development of genetic animal models of colitis demonstrate diverse disturbances of immunity and intestinal barrier 
function capable of inducing a phenotype of gut inﬂ  ammation
•    Animal models demonstrate the central role of gut ﬂ  ora as a necessary factor in colitis, with the ﬂ  ora further implicated in 
serologic studies in humans
•   NOD2/CARD15 demonstrated as the ﬁ  rst disease-associated gene in Crohn’s disease after IBD1 localized to chromosome 
16 by genomewide scanning
•  Defective innate immune response implicated in Crohn’s disease by NOD2 physiology
•  Biologic agents developed through monoclonal antibody technology and molecular biology techniques
• Inﬂ  iximab, the ﬁ  rst of a new class of anti-TNF biologics, shown to be effective in Crohn’s disease and ulcerative colitis
•  The heterogeneity of Crohn’s disease and ulcerative colitis demonstrated in genetic and serologic studies
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smoke as a factor capable of modifying the expression 
of inﬂ  ammation in the gut.32
Circumstantial evidence has long pointed to the criti-
cal role of the luminal ﬂ  ora in IBD. The evidence is 
strongest in Crohn’s disease and relatively sparse in ul-
cerative colitis. In clinical practice antibiotics are widely 
used to treat perianal disease in Crohn’s disease.33 Evi-
dence from clinical trials suggests some effect of antibi-
otic therapy as a treatment for Crohn’s disease, primarily 
in disease with colonic localization.34 In addition, imid-
azole antibiotics such as metronidazole35  and ornida-
zole36 have been demonstrated reproducibly to have a 
prophylactic effect for disease recurrence after ileal re-
section. Furthermore, as noted above, a time-honored, 
though outmoded technique to treat refractory Crohn’s 
disease has been to surgically divert the affected seg-
ment. Experiments carried out in the 1980s demon-
strated that the luminal contents contained factors, 
most likely bacterial factors, capable of reinducing in-
ﬂ  ammation in quiescent diverted bowel.37 In addition, 
elemental diet has been demonstrated to be an effective 
therapy for Crohn’s disease.38 Effects of elemental diet 
may be complex, but are thought to include a favorable 
effect on the bowel ﬂ  ora composition that may mini-
mize immunologic stimulation of the host immune re-
sponse. Another line of research being vigorously 
pursued is the potential role of probiotic therapies as 
treatments for IBD. Thus far, clinical trials in humans 
have not demonstrated a robust effect of these agents 
in IBD. The clearest demonstration of beneﬁ  t has been 
with a preparation known as VSL#3 in the treatment 
and prophylaxis of pouchitis occurring in ileal pouches 
created as curative therapy for ulcerative colitis.39,40 
Other studies have suggested modest beneﬁ  t in ulcer-
ative colitis and Crohn’s disease for a variety of probi-
otic agents, including Nissle 1917 and VSL#3.41,42 Finally, 
one intriguing study demonstrated excessive respon-
siveness of lamina propria mononuclear cells to autolo-
gous gut bacteria among patients with IBD.43
Animal models of colitis have also provided essential 
clues to the role of the luminal ﬂ  ora in the pathogenesis 
of IBD. The list of genetic and acquired aberrations that 
culminate in phenotypic manifestations of intestinal in-
ﬂ  ammation is strikingly long and diverse.44 These mod-
els include animals with disturbed immune regulation, 
such as the interleukin (IL)-2, T-cell receptor α and IL-
10 knockouts, as well as models where disruption of the 
epithelial barrier function is paramount, such as the 
G2αi knockout mouse. The sheer diversity of abnor-
malities that drive intestinal inﬂ  ammation reminiscent 
of human IBD suggests that the gut has a limited phe-
notypic repertoire and is capable of expressing such 
disturbances in only a limited number of ways. The 
corollary is that human IBD may also be two pheno-
typic syndromes driven by diverse genetic abnormali-
ties. This is clearly suggested by observations of genetic 
and serologic heterogeneity among individuals diag-
nosed with ulcerative colitis or Crohn’s disease.45–48
In addition, the role of the intestinal ﬂ  ora in driving 
gut mucosal inﬂ  ammation has been clearly demonstrat-
ed in these diverse models. In every model thus far ex-
plored, it is clear that removing intestinal ﬂ  ora from the 
equation by raising animal lines in gnotobiotic condi-
tions greatly diminishes or prevents the onset of gut 
inﬂ  ammation. With the introduction of nonpathogenic 
bacteria, each of these models then proceeds to mani-
fest their typical phenotype of colonic inﬂ  ammation. It 
does not appear to be the case that pathogenic micro-
biota are necessary to drive the disease. Furthermore, 
it has become clear that the characteristics of the intes-
tinal ﬂ  ora also shape the phenotypic characteristics of 
the gut inﬂ  ammation. For example in the HLA B27 
transgenic rat, monoassociation experiments with sin-
gle, nonpathogenic bacterial species have been per-
formed. The introduction of Bacteroides vulgatus results 
in a moderately severe colitis, whereas the introduction 
of E. coli results in no colitis whatsoever. Colonization 
with the entire mixture of the usual bacterial ﬂ  ora pres-
ent in the cecum culminates in an aggressive colitis, 
whereas the introduction of cecal bacteria plus the pro-
biotic species Lactobacillus GG  results in protection 
from colitis altogether.49 These experiments suggest that 
speciﬁ  c nonpathogenic bacteria may shape the expres-
sion of disease severity in profound ways.
Surprisingly, it also appears that speciﬁ  c nonpatho-
genic bacteria may also be a determinant of anatomic 
disease localization. IL-10 knockout mice grown in 
germ-free conditions do not typically manifest colitis. 
With the introduction of commensal ﬂ  ora, the typical 
colonic inﬂ  ammatory phenotype ensues. However, 
when monocolonization with Enterococcus faecalis oc-
curs, a left-sided colitis ensues. Alternatively, upon 
colonization with E. coli, a distinctly right-sided colitis 
occurs.50 Together, these ﬁ  ndings suggest that the com-
position of the commensal ﬂ  ora may have a major im-
pact on the phenotypic expression of IBD.
It cannot be assumed that the genetic aberrations in 
gene knockout or knock-in models of colitis are reﬂ  ec-
tive of the actual genetic polymorphisms that cause hu-
man disease. However, great strides have been made in 
the identiﬁ  cation of genetic defects associated with 
Crohn’s disease and ulcerative colitis. The inﬂ  ammatory 
bowel diseases have long been understood to be com-
plex polygenic diseases. The greatest progress has been 
made to the application of genomewide scanning, which 
has been greatly facilitated by the development of mic-
rosatellite markers and more recently single-nucleotide 
polymorphism (SNP) haplotype maps of the human ge-
nome. With the collaboration of numerous genetics re-
search groups across the globe, speciﬁ  c genetic loci with 20  B.E. Sands: Inﬂ  ammatory bowel disease
strong associations with IBD have been discovered.51 
This approach is distinct from the candidate gene ap-
proach, which explores genetic polymorphisms in a 
gene that is predicted to be of particular interest by 
virtue of its known function. Rather, the greatest prog-
ress has been made by an unbiased appraisal of the hu-
man genome afforded by genomewide scanning. Using 
these techniques, the ﬁ  rst such IBD gene identiﬁ  ed was 
the  NOD2/CARD15  gene on chromosome 16, asso-
ciated with the IBD1 locus found on genomewide 
scanning.52–54 Speciﬁ  c disease associated polymorphisms 
included the R702W, G908R, and ∆33 mutations associ-
ated with relative risks for Crohn’s disease of 14.3, 34.1, 
and 17.64 for homozygous recessive individuals over 
control populations.52–54
Explication of the cellular function of NOD2 has shed 
light on the nature of the underlying immune defects of 
Crohn’s disease. NOD2 (nuclear type binding oligomer-
ization domain 2) consists of two CARD domains, fol-
lowed by a NOD domain, and ending in a leucine-rich 
repeat. It is within the leucine-rich repeat domain that 
the disease-associated mutations have been noted. 
These are loss-of-function mutations, which appear to 
prevent the binding of muramyl dipeptide, which is 
ubiquitously present in virtually all bacterial cell walls.55 
Downstream events lead to the activation of NFκB 
through an interaction with the CARD domains.56 Thus, 
it appears that NOD2 is intimately involved in intracel-
lular bacterial sensing and generation of the innate 
immune response.57
Less certain is how a loss-of-function mutation in the 
leucine-rich repeat causes the inﬂ  ammation of Crohn’s 
disease. Although many hypotheses have been gen erated 
regarding the mechanism of disease, none have been 
conclusively proven. One hypothesis is that with the loss 
of binding of muramyl dipeptide to NOD2, there is a 
compensatory response with failure to inhibit the activa-
tion of c-Rel and p50 by binding of peptidoglycan to the 
toll-like receptor 2.58 This results in the downstream ac-
tivation of IL-12 and consequent inﬂ  ammation.
Regardless of the precise mechanism through which 
NOD2 polymorphisms generate a Crohn’s disease phe-
notype, this discovery has brought the role of the innate 
immune responses to the fore. The innate immune re-
sponses are the hardwired and immediate responses to 
pathogens that occur through binding of pathogen-
associated molecular patterns to cell-bound receptors. 
The critical cellular elements in this response include 
macrophages, NK cells, and nonprofessional antigen-
presenting cells. By contrast, much research of the last 
20 years has focused on the adaptive immune system. 
The adaptive immune responses require priming and 
the generation of antigen-speciﬁ  c responses by B and T 
cells, and therefore may not be immediate. Although 
cell-to-cell surface interactions may occur, soluble 
factors may also play a role in adaptive immune 
responses.
The dendritic cells of the gut have become a focal 
point in our understanding of intestinal immune 
responses.59  Elegant immunoﬂ  uorescent microscopic 
techniques have demonstrated large populations of 
dendritic cells localized just beneath the intestinal epi-
thelial cells.60 These arborized cells project long podo-
cytes through the interstices of the intestinal epithelial 
cells and out to the intestinal lumen. Here, extensive 
sampling of luminal antigens occurs. It is believed that 
the dendritic cells process these antigens, and then pres-
ent them to the cells in the Peyer’s patches as well as in 
the mesenteric lymph nodes. Depending upon the na-
ture of the antigen and the activation state of the den-
dritic cell, the end result may be immune activation or 
tolerization. Enterocytes may also present antigen, also 
likely leading to tolerization,61  whereas pathogenic 
microbes traversing M cells to the underlying Peyer’s 
patches are likely to trigger immune activation.62
In parallel to the growing importance of the innate 
immune system came the ﬁ  rst studies of therapies in-
tended to enhance the innate immune responses, rather 
than to suppress adaptive immune responses. Korzenik 
and Dieckgraefe63 reexamined data from the 1970s and 
1980s that suggested that neutrophil responses were di-
minished in patients with Crohn’s disease. In addition, 
they noted that varied conditions characterized by 
neutrophil defects are also commonly associated with 
Crohn’s disease or a Crohn’s disease-like phenotype. 
They reasoned, therefore, that individuals with Crohn’s 
disease may also have neutrophil defects, and that stim-
ulating neutrophils may be beneﬁ  cial in the treatment 
of Crohn’s disease. This hypothesis led them to test 
granulocyte-colony stimulating factor (G-CSF) and 
granulocyte-macrophage (GM)-CSF in open-label pilot 
trials in Crohn’s disease, with promising early results.64,65 
A subsequent phase 2 study of sargramostim (GM-CSF) 
in Crohn’s disease demonstrated evidence of activity of 
this agent in decreasing symptoms of active disease.66 
Unfortunately, a phase 3 study failed to demonstrate 
efﬁ  cacy over placebo, although a separate study dem-
onstrated efﬁ  cacy of this agent in steroid sparing.67
More detailed descriptions of the immunologic path-
ways of the adaptive immune responses in Crohn’s dis-
ease and ulcerative colitis have also led to new and 
speciﬁ  c therapeutic agents. In the early 1990s, animal 
models of immunologic disease demonstrated that T 
helper (Th) cell populations segregated according to 
distinct cytokine proﬁ  les.68 Th1 cells are characterized 
by the expression of IL-2, interferon-γ, IL-12, and tumor 
necrosis factor (TNF) α. Th1 responses are most closely 
associated with the cell-mediated immune responses 
that characterize Crohn’s disease.69 By contrast, Th2 re-
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a cytokine proﬁ  le comprising IL-4, IL-5, IL-6, and IL-
13. The cytokine proﬁ  le expressed in ulcerative colitis 
tissues is most consistent with a variation on Th2-like 
immune responses, lacking in the expression of IL-4.69
Understanding the role of cytokines has been a criti-
cal advance in IBD therapeutics, along with the advent 
of monoclonal antibody technology, which made possi-
ble the targeted inhibition of speciﬁ  c disease-related 
cytokines. Furthermore, it has been possible to give 
inhibitory cytokines as therapeutic agents. Clearly, the 
greatest advance in this area has been the advent of 
anti-TNF biologic therapies.
Early reports from the Netherlands described two 
cases of Crohn’s disease treated with a chimeric mono-
clonal anti-TNF antibody called cA2.70  This was fol-
lowed by a case series of ten patients with Crohn’s 
disease, who experienced a high rate of response and 
rapid mucosal healing on endoscopy.71  The ﬁ  rst ran-
domized controlled trial by Targan et al.72 demonstrated 
that short-term induction occurred rapidly and in the 
majority of patients with active disease unresponsive to 
other therapies. However, the majority of patients re-
lapsed at a median time of 8 weeks. This, in turn, neces-
sitated the investigation of strategies for maintaining 
response. The ACCENT I73 and ACCENT II74 studies 
demonstrated the ability to maintain a durable response 
in a subset of patients with nonﬁ  stulizing and ﬁ  stulizing 
Crohn’s disease, respectively, over the course of a year 
of follow-up.
One of the drawbacks of chimeric monoclonal anti-
body therapy has been the generation of immune re-
sponses against the drug and loss of response. Newer 
agents have been developed with ostensibly more 
human protein sequence and structure. These include 
adalimumab, a fully human anti-TNF antibody,75 and 
certolizumab, a pegylated Fab  anti-TNF fragment.76 
Whether these agents are less immunogenic than inﬂ  ix-
imab is as yet uncertain. However, ﬁ  ndings of long-term 
studies lasting from 6 to 12 months suggest that the ef-
ﬁ  cacy of these agents is equivalent to that seen with in-
ﬂ  iximab.77,78 Other issues with the anti-TNF biologics 
relate to weighing the risks and beneﬁ  ts of these agents 
for speciﬁ  c patients.79 Described risks include rare oc-
currence of opportunistic infections, including intracel-
lular infections such as tuberculosis and fungal and viral 
infections, demyelinating disorders, and rare reports of 
lymphoma.80 It will be critical to deﬁ  ne populations for 
whom these risks are appropriate, or alternatively to 
identify patients at least risk for developing these 
complications.
Other cytokine-directed therapies are at earlier stag-
es of development. Randomized controlled trials with 
daily subcutaneous injections of IL-10 provided disap-
pointingly negative results.81 This result was unexpected 
after initially promising phase 2 studies, and especially 
given that the preclinical rationale of using this classic 
inhibitory cytokine was quite strong. In addition, stud-
ies using the humanized anti-IL-2 receptor antibody 
daclizumab showed this agent to be ineffective as a 
treatment for ulcerative colitis.82 Early studies with anti-
IL-12 antibody appear to demonstrate some activity in 
active Crohn’s disease.83 This agent, which binds to epi-
topes in the p40 subunit of IL-12, may also bind to the 
same subunit as a component of the heterodimeric pro-
inﬂ  ammatory cytokine IL-23. Of note, the IL-23 recep-
tor gene was recently associated with Crohn’s disease; 
namely, polymorphisms in this gene appear to confer 
protection against the disease.84 This would suggest that 
agents that inhibit IL-23 may prove to be effective in 
Crohn’s disease.
A second area where understanding of the pathogen-
esis has led to novel therapies is in the area of cellular 
adhesion and recruitment. Although a normal state of 
physiologic inﬂ  ammation exists in the mucosa of the 
bowel, it is only through the coordinated expression of 
speciﬁ  c adhesion molecules that cells are recruited from 
the peripheral circulation into the mucosa in response 
to inﬂ  ammation. In the early 1990s, the details of cellu-
lar recruitment and adhesion were explicated in ﬁ  ne 
detail.85 When inﬂ  ammation is present within a tissue, a 
series of events occur in rapid succession. First, the en-
dothelium becomes activated, and the expression of E- 
and P-selectins on the endothelial surface expression 
occurs. L-selectin on the cell surface of leukocytes in 
circulation binds weakly to the selectins expressed on 
the endothelium. This, in turn, causes rolling of the 
leukocyte along the endothelial surface and activation 
of integrin expression on the leukocyte surface.85 The 
integrins then bind tightly to cellular adhesion mole-
cules such as VCAM, ICAM, and MAdCAM86 on the 
endothelial surface. Finally, the leukocytes diapedese 
into the mucosa. Here, chemokines exist in a gradient 
within the mucosa, guiding the leukocytes further to-
ward the mucosal surface. Thus, adhesion and recruit-
ment of leukocytes is a complex and critical process in 
inﬂ  ammation that offers many potential targets for spe-
ciﬁ  c interventions against inﬂ  ammation.
The ﬁ  rst agent to have targeted adhesion was the 
humanized anti-α4 integrin antibody natalizumab. A 
large phase 2 study of natalizumab in Crohn’s disease 
appeared to demonstrate short-term activity but failed 
to meet its primary end point in a statistically signiﬁ  cant 
way.87 A follow-up phase 3 study again demonstrated 
activity of this agent, but missed its primary end point, 
in large part owing to a high placebo response rate.88 
However, a follow-on study demonstrated robust 
maintenance efﬁ  cacy with natalizumab.88 An additional 
short-term study ﬁ  nally conﬁ  rmed the efﬁ  cacy of natali-
zumab among patients with elevated C-reactive pro-
tein.89 Unexpectedly, however, three cases of progressive 22  B.E. Sands: Inﬂ  ammatory bowel disease
multifocal leukoencephalopathy (PML), an otherwise 
extremely rare and usually fatal central nervous system 
disease caused by the JC virus, were found among 3000 
patients treated for either multiple sclerosis or Crohn’s 
disease with this agent.90
A second selective adhesion molecule inhibitor, 
MLN-02, has been demonstrated in a phase 2 study to 
be efﬁ  cacious in patients with active ulcerative colitis 
failing treatment with 5-aminosalicylates.91  A second 
pilot study was performed in Crohn’s disease with 
promising effect.92  At this time, it is unknown if the 
more speciﬁ  c adhesion of this antibody to α4β7 integrin, 
the ligand of MAdCAM (mucosal addressin cellular 
adhesion molecule, located only in gut endothelium), 
will improve the safety proﬁ  le of this agent and avoid 
the occurrence of PML.
A third area of interest for therapeutic intervention 
is the process of T-cell activation. The interactions be-
tween antigen-presenting cells and T cells may be con-
ceived of as being analogous to a neurological synapse. 
As with the neuronal synapse, a variety of stimulatory 
and inhibitory signals are integrated when the antigen-
presenting cell interacts with a T cell, yielding a net 
overall effect of activation or inhibition of the immune 
response.93,94 The basis of the antigen-speciﬁ  c response 
occurs with the presentation of an antigenic epitope in 
the context of major histocompatibility complex (MHC) 
class II. MHC class II/antigen binds to the T-cell recep-
tor CD3 in an antigen-speciﬁ  c fashion. However, this 
primary signal is not sufﬁ  cient in itself to activate the 
naïve T cell. Rather, the presence of a costimulatory 
signal is necessary for activation to occur. These include 
binding of TNF receptor to TNF on the cell surface, 
CD40 ligand to CD40, and B7 to the costimulation re-
ceptor CD28.94  When such costimulatory signals are 
lacking, the end result is anergy or apoptosis of the T 
cell rather than activation.
Both the antigen-speciﬁ  c interaction of MHC class 
II-CD3 and the costimulatory signals offer opportuni-
ties for therapeutic intervention. The humanized anti-
CD3 antibody visilizumab has been explored as a 
treatment for refractory ulcerative colitis.95 Open-label 
studies suggest that this agent may be efﬁ  cacious even 
in situations where disease is severe and unresponsive 
to steroids. Visilizumab is highly potent, with activity 
seen at doses as low as 5  µg per kilogram. A cytokine-
release syndrome has been observed with this agent. 
The long-term safety consequences of lysing activated 
T cells have yet to be determined, as studies have been 
relatively small and of short duration.
Other strategies have attempted to target the costim-
ulatory signal rather than the T-cell receptor. An alter-
native costimulatory interaction of some interest is the 
binding of CD28 to B7. Abatacept is a fusion molecule 
of CTL4 and immunoglobulin, known as CTLA-Ig.96 
This agent is approved in the United States for the 
treatment of rheumatoid arthritis and has been shown 
to be effective in patients who have not responded to 
anti-TNF biologic agents in that disease state.96 In prin-
ciple, this agent would be of considerable interest as a 
potential therapy for IBD.
As yet untapped are therapies that might exert thera-
peutic effect by enhancing regulatory T cells as opposed 
to inhibiting effector T cells. There is a growing appre-
ciation for various populations of T cells that exert a 
downregulatory effect on immune responses and do so 
through a variety of mechanisms. Distinct populations 
have been recognized as including Tr1 cells, character-
ized by elaboration of IL-10,97 Th3 cells,98 characterized 
by membrane-bound transforming growth factor β, and 
CD4+ CD25+ T regulatory cells, which inhibit through 
direct cell-to-cell contact.99 The earliest exploration of 
this therapeutic principle may involve the selection and 
engineering of T cells to deliver IL-10.100 The clinical 
efﬁ  cacy and safety of this approach is as yet unknown.
In summary, in recent times we have learned that the 
intestinal ﬂ  ora is critical in generating the immune re-
sponse of IBD. In Crohn’s disease, the innate immune 
response appears to be defective in some patients. An 
excess of effector T cells, characterized as either Th1- or 
Th2-like, is associated with the distinct clinical manifes-
tations of Crohn’s disease and ulcerative colitis, respec-
tively. We have teased out cytokine pathways that shape 
and perpetuate inﬂ  ammation. The process of leukocyte 
adhesion and recruitment has been worked out. T regu-
latory responses have been shown to be deﬁ  cient in 
IBD. These detailed explanations of the pathogenesis 
of IBD have led to more effective and focused treat-
ments for these diseases.
Future: the era of prediction
Increasingly, we are entering a time when high-through-
put technologies are revolutionizing the approach to 
medical discovery. No longer are candidate proteins 
and genes laboriously discovered and evaluated in iso-
lated systems. High-throughput DNA sequencers are 
capable of sequencing an individual genome in days 
rather than years. Gene expression arrays simultane-
ously represent the expression of thousands of tran-
scripts rather than a handful at a time. Mass spectrometry 
combined with other techniques permits the simul-
taneous determination of thousands of proteins in a 
burgeoning area known as proteomics. Hundreds of 
metabolites can be determined in biologic specimens 
through the methodologies of metabolomics. Nonclas-
sical microbiologic techniques based upon molecular 
biology will facilitate an improved understanding of the 
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The completion of the Human Genome Project and 
SNP haplotype mapping101 have made it possible to ex-
amine individual genotypes in relation to disease sus-
ceptibility as well as disease characteristics and prognosis. 
Rather than starting from a prior hypothesis about a 
single gene, protein, or metabolite playing a role in the 
disease process, unbiased explorations of all possible 
biologic variations may be explored. Advances in bio-
informatics and the ability to integrate the volumes 
of data generated by such experiments will be critical 
in allowing medicine to progress to the point where 
personalized medicine may become fact rather than 
aspiration.
When these new techniques have been more fully 
applied to the problems of patients with IBD, it is likely 
that we will improve both prediction of individual prog-
noses for the disease, as well as be able to target therapy 
to the mechanism of disease. We will no longer blithely 
talk about curing Crohn’s disease or ulcerative colitis; 
rather, it is very likely that we will talk about very spe-
ciﬁ  c cures for each one of the many varied genetic or 
acquired aberrations that cause the Crohn’s disease or 
ulcerative colitis phenotype. We will also ﬁ  nally eluci-
date the environmental factors that have contributed to 
the rise of these diseases in Westernized societies.
In summary, a survey of the past and present ad-
vances in the inﬂ  ammatory bowel diseases provides 
much cause for optimism. The accelerating pace of dis-
covery in Crohn’s disease and ulcerative colitis provides 
hope that each year will bring a better life to the grow-
ing number of individuals who suffer from these curious 
diseases.
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